This is a Phase 1, open-label, single-dose, mass balance study designed to evaluate the absorption, metabolism, and excretion of \[14C\] radiolabeled LC350189 after oral administration.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
6
Carbon-14 labelded LC350189
PPD
Austin, Texas, United States
Mass balance recovery of total radioactivity in whole blood and plasma.
Radioactivity is measured by radiation dosimetry.
Time frame: Before dosing on Days 1 through Day 10 (240 hours)
Mass balance recovery of total radioactivity in whole urine, and feces.
Radioactivity is measured by radiation dosimetry.
Time frame: Before dosing on Days 1 through Day 10 (240 hours)
Incidence of adverse events
Safety
Time frame: form baseline up to Day 11
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.